Across TCGA pan-cancer cohorts, IGHV4-34 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated IGHV4-34 data layer compared with 22 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in sarcoma (SARC), where higher IGHV4-34 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated IGHV4-34 expression acts as an unfavorable survival marker.

SARC, LUAD, and SKCM are the cancer types where IGHV4-34 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SARC	DFS	Median	All	0.121	0.591	.042	3	view →
LUAD	OS	Median	II,III,IV	0.307	0.748	.046	3	view →
SKCM	DFS	Median	II,III,IV	0.219	0.711	.010	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: IGHV4-34 tumor-vs-normal RNA expression · all IGHV4-34 data types